Russell D. Cohen to Inflammatory Bowel Diseases
This is a "connection" page, showing publications Russell D. Cohen has written about Inflammatory Bowel Diseases.
Connection Strength
4.902
-
Checking Out the Associations Between Inflammatory Bowel Disease and Checkpoint Inhibitor Colitis. Dig Dis Sci. 2022 Nov; 67(11):5010-5013.
Score: 0.552
-
AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary. Gastroenterology. 2020 Jul; 159(1):350-357.
Score: 0.467
-
The pharmacoeconomics of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol. 2010 Feb; 7(2):103-9.
Score: 0.230
-
Optimizing conventional therapy for inflammatory bowel disease. Curr Gastroenterol Rep. 2008 Dec; 10(6):585-90.
Score: 0.212
-
Pharmacoeconomic considerations for inflammatory bowel disease in the era of biological therapies. Expert Rev Gastroenterol Hepatol. 2007 Oct; 1(1):101-12.
Score: 0.196
-
Economics of the use of biologics in the treatment of inflammatory bowel disease. Gastroenterol Clin North Am. 2006 Dec; 35(4):867-82.
Score: 0.185
-
Sperm, sex, and 6-MP: the perception on conception. Gastroenterology. 2004 Oct; 127(4):1263-4.
Score: 0.159
-
Delays in Therapy Associated With Current Prior Authorization Process for the Treatment of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2023 10 03; 29(10):1658-1661.
Score: 0.149
-
IBD indirect costs: the sleeping giant? Gastroenterology. 2003 Sep; 125(3):982-4.
Score: 0.148
-
Antigen-driven colonic inflammation is associated with development of dysplasia in primary sclerosing cholangitis. Nat Med. 2023 Jun; 29(6):1520-1529.
Score: 0.145
-
IBD: the drugs work...but do the patients? Am J Gastroenterol. 2003 Apr; 98(4):722-3.
Score: 0.143
-
Methotrexate in IBD--move over 6-MP? Not so fast... Gastroenterology. 2002 Nov; 123(5):1737-9.
Score: 0.139
-
Endo-histologic Normalization Is Achievable with Tofacitinib and Is Associated with Improved Clinical Outcomes. Dig Dis Sci. 2023 04; 68(4):1464-1472.
Score: 0.139
-
Forecast for using metabolite measurements in the dosing of azathioprine or 6-mercaptopurine for IBD patients: "partly cloudy". Gastroenterology. 2002 Jun; 122(7):2082-4; discussion 2084.
Score: 0.135
-
Prospective Cohort Study to Investigate the Safety of Preoperative Tumor Necrosis Factor Inhibitor Exposure in Patients With Inflammatory Bowel Disease Undergoing Intra-abdominal Surgery. Gastroenterology. 2022 07; 163(1):204-221.
Score: 0.134
-
Endoscopy in inflammatory bowel disease. Gastroenterol Clin North Am. 2002 Mar; 31(1):119-32.
Score: 0.133
-
Endoscopic Phenotype of the J Pouch in Patients With Inflammatory Bowel Disease: A New Classification for Pouch Outcomes. Clin Gastroenterol Hepatol. 2022 02; 20(2):293-302.e9.
Score: 0.124
-
Letter: is unrealised adult height resulting from paediatric Crohn's disease associated with a potential reduction in lifetime earnings? Aliment Pharmacol Ther. 2020 08; 52(3):559-560.
Score: 0.119
-
Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2020 06; 51(12):1365-1372.
Score: 0.117
-
The role of laparoscopy and strictureplasty in the management of inflammatory bowel disease. Semin Gastrointest Dis. 2000 Jan; 11(1):10-7.
Score: 0.114
-
Faecal Calprotectin Is a Very Reliable Tool to Predict and Monitor the Risk of Relapse After Therapeutic De-escalation in Patients With Inflammatory Bowel Diseases. J Crohns Colitis. 2019 Aug 14; 13(8):1012-1024.
Score: 0.111
-
Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. J Gastroenterol Hepatol. 2019 Dec; 34(12):2090-2095.
Score: 0.111
-
Targeted mutational analysis of inflammatory bowel disease-associated colorectal cancers. Hum Pathol. 2019 07; 89:44-50.
Score: 0.109
-
Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2019 02; 17(3):486-493.
Score: 0.102
-
Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study. Dig Dis Sci. 2018 04; 63(4):1016-1024.
Score: 0.100
-
Use of Biologic Therapy by Pregnant Women With Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines. Clin Gastroenterol Hepatol. 2018 Jan; 16(1):99-105.
Score: 0.097
-
Factors associated with readmission to the hospital within 30 days in patients with inflammatory bowel disease. PLoS One. 2017; 12(8):e0182900.
Score: 0.097
-
Risk of Postoperative Complications Among Inflammatory Bowel Disease Patients Treated Preoperatively With Vedolizumab. Am J Gastroenterol. 2017 Sep; 112(9):1423-1429.
Score: 0.097
-
The incidence and predictors of lupus-like reaction in patients with IBD treated with anti-TNF therapies. Inflamm Bowel Dis. 2013 Dec; 19(13):2778-86.
Score: 0.075
-
[American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease]. Rev Gastroenterol Mex. 2006 Jul-Sep; 71(3):351-401.
Score: 0.045
-
MLN-02 in IBD: is "super-selective" really super? Gastroenterology. 2006 May; 130(6):1923-4.
Score: 0.044
-
American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006 Mar; 130(3):935-9.
Score: 0.044
-
American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006 Mar; 130(3):940-87.
Score: 0.044
-
Mesalamine delivery systems: do they really make much difference? Adv Drug Deliv Rev. 2005 Jan 06; 57(2):281-302.
Score: 0.041
-
The Effect of Maternal Peripartum Anti-TNFa Use on Infant Immune Response. Dig Dis Sci. 2016 06; 61(6):1622-7.
Score: 0.022
-
Ulcerative Colitis Care Pathway. Gastroenterology. 2015 Jul; 149(1):238-45.
Score: 0.021